• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Scott N. Gettinger, Leora Horn, +26 authors Julie R. Brahmer
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2015 (First Publication: 20 April 2015)
  • PURPOSE Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was activeContinue Reading
  • David Robert Spigel, Thomas J. Ervin, +17 authors Amy C. Peterson
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2013 (First Publication: 10 November 2013)
  • PURPOSE Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal growth factor receptor (EGFR) -targeted drugs in patients withContinue Reading
  • Joel Randolph Hecht, Edith P. Mitchell, +10 authors Rafael G. Amado
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2009 (First Publication: 10 February 2009)
  • PURPOSE Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added toContinue Reading
  • Lecia V. Sequist, Renato G. Martins, +16 authors Thomas James Lynch
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2008 (First Publication: 20 May 2008)
  • PURPOSE Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with increased response in patients with non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinaseContinue Reading
  • Martin Reck, Alexander V Luft, +17 authors David Robert Spigel
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2016 (First Publication: 25 July 2016)
  • Purpose Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blindContinue Reading
  • Leora Horn, David Robert Spigel, +26 authors Wilfried Ernst Erich Eberhardt
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2017 (First Publication: 12 October 2017)
  • Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamousContinue Reading
  • Charles M. Rudin, Maria Catherine Pietanza, +20 authors David Robert Spigel
  • Medicine
  • The Lancet. Oncology
  • 2017
  • BACKGROUND Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in moreContinue Reading